1. Home
  2. PCRX vs NEO Comparison

PCRX vs NEO Comparison

Compare PCRX & NEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Pacira BioSciences Inc.

PCRX

Pacira BioSciences Inc.

N/A

Current Price

$22.83

Market Cap

1.0B

Sector

Health Care

ML Signal

N/A

Logo NeoGenomics Inc.

NEO

NeoGenomics Inc.

N/A

Current Price

$8.55

Market Cap

1.2B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
PCRX
NEO
Founded
2006
2001
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Precision Instruments
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.0B
1.2B
IPO Year
2010
2008

Fundamental Metrics

Financial Performance
Metric
PCRX
NEO
Price
$22.83
$8.55
Analyst Decision
Strong Buy
Buy
Analyst Count
6
7
Target Price
$35.33
$11.14
AVG Volume (30 Days)
736.7K
1.9M
Earning Date
01-01-0001
05-18-2026
Dividend Yield
N/A
N/A
EPS Growth
107.44
N/A
EPS
0.16
N/A
Revenue
$541,533,000.00
N/A
Revenue This Year
$9.77
$10.63
Revenue Next Year
$9.71
$9.73
P/E Ratio
$140.38
N/A
Revenue Growth
26.04
N/A
52 Week Low
$18.80
$4.72
52 Week High
$27.99
$13.74

Technical Indicators

Market Signals
Indicator
PCRX
NEO
Relative Strength Index (RSI) 52.95 23.47
Support Level $20.41 $7.07
Resistance Level $23.82 $8.89
Average True Range (ATR) 1.01 0.46
MACD 0.02 -0.08
Stochastic Oscillator 68.81 2.75

Price Performance

Historical Comparison
PCRX
NEO

About PCRX Pacira BioSciences Inc.

Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.

About NEO NeoGenomics Inc.

NeoGenomics Inc provides oncology diagnostic testing and consultative services which include technical laboratory services and professional interpretation of laboratory test results by licensed physicians or molecular experts in pathology and oncology. The company operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company operates in a single segment and derives revenue from clients by providing clinical cancer testing, interpretation, and consultative services, molecular and NGS testing, comprehensive technical and professional services offerings, clinical trials and research, validation laboratory services, and oncology data solutions.

Share on Social Networks: